All needs to be said by them has been said already. It is now just a matter of waiting for the trial outcome. Until the right amount of data is acquired, no amount of analysis is going to be complete and true.
I suppose the main thing is that the company is travelling in the right direction as rather good speed. Each announcements has confirmed more and more that both the CF33 and Azercel platforms are doing fine. When compelling data is finally released, then the BP will make their move. For example, if the OnCarlytics/Blincyto combo trial shows much better outcome than Blincyto alone, then Amgen will most likely make a move. Just a matter of when.
All in all, should not be too long now (in biotech term).
In conclusion, IMU will always be better than RAC. And I still will not touch RAC with a 100m pole! It is that toxic.
IMU Price at posting:
4.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)